Dual JAK-PDE4 Boron Compounds for Inflammatory Skin Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory skin diseases like atopic dermatitis lack a standard of care and are limited by adverse effects, and there is a need for novel therapeutic strategies targeting Janus kinases (JAK) and phosphodiesterase-4 (PDE4) to effectively manage inflammation and autoimmune diseases.
Innovation Solution
Development of boron-containing compounds that act as dual inhibitors of JAK and PDE4, or in combination with tyrosine kinases such as TrkA and Syk, to modulate immune responses and reduce inflammation in diseases susceptible to inhibition of JAK optionally in conjunction with one or more other mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids are used as first-line treatment for atopic dermatitis, then anti-inflammatory effect is achieved, but local and systemic adverse effects occur
Solution Approach 1:
The patent changes the chemical parameters by developing novel boron-containing compounds with dual JAK and PDE4 inhibition capabilities, representing a fundamental shift from traditional corticosteroid mechanisms to a new chemical class with different safety profiles
Solution Approach 2:
The invention creates multi-functional compounds that simultaneously inhibit both JAK and PDE4 enzymes, providing dual anti-inflammatory mechanisms in a single agent, thereby achieving broader therapeutic effects while potentially reducing adverse effects associated with single-mechanism treatments
2Duration of action of stationary object
If topical calcineurin inhibitors are used as second-line therapy for atopic dermatitis, then long-term maintenance is achieved, but potential for developing malignant neoplasms occurs
Solution Approach 1:
The patent fundamentally changes the therapeutic mechanism by targeting JAK and PDE4 pathways instead of calcineurin, thereby maintaining long-term therapeutic efficacy while eliminating the carcinogenic risk associated with calcineurin inhibition
Solution Approach 2:
The invention converts the harmful side effect profile of existing long-term treatments into a benefit by developing compounds with a fundamentally different mechanism of action that achieves sustained therapy without the carcinogenic risks of calcineurin inhibitors
3Adaptability or versatility
If dual inhibitors of JAK and PDE4 are developed, then unique anti-inflammatory profile is achieved, but compound complexity increases
Solution Approach 1:
The patent merges two distinct inhibitory functions (JAK and PDE4) into a single molecular entity, creating a dual-action compound that provides unique anti-inflammatory properties while consolidating multiple mechanisms into one therapeutic agent
Solution Approach 2:
The invention designs universal compounds capable of inhibiting both JAK and PDE4 enzymes through carefully selected molecular structures containing boron-containing groups and specific heterocyclic systems that provide broad enzymatic inhibition
Data Source
AI summary
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.